Lexaria now holds 37 granted patents world-widePotential application in treating nicotine addictionKELOWNA, BC / ACCESSWIRE / October 12, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted two new patents by the Canadian Intellectual Property Office ("CIPO"), increasing Lexaria's complete patent portfolio to 37 granted...
Read more
Live moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, October 25th at 12:00 PM ETIRVINE, CA / ACCESSWIRE / October 12, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, will participate at the Virtual Investor Ask the...
Read more
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 12, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following update with its M2MMA division: M2MMA, the latest division of...
Read more
Aronora is Revolutionizing Blood Clot Treatment with Groundbreaking InnovationsPORTLAND, OR / ACCESSWIRE / October 12, 2023 / Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center. The funding will support team expansion, manufacturing, and regulatory activities as Aronora prepares for...
Read more
UPPSALA, SE / ACCESSWIRE / October 12, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida.This center in Florida is part of a large and well renowned organization that serves all 50 states in US and international representation as well. In total,...
Read more
Live moderated webcast with Roelof Rongen, Chief Executive Officer of Adolore BioTherapeutics on Wednesday, October 25th at 3:00 PM ETDELRAY BEACH, FL / ACCESSWIRE / October 11, 2023 / Adolore BioTherapeutics ("Adolore" or the "Company"), a company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roelof Rongen, CEO of Adolore, will participate at the Virtual Investor Ask the CEO...
Read more
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive...
Read more
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to effect a one-for-seven reverse share split of its common shares. The Company's common shares will continue to be traded on The Nasdaq Capital Market under the symbol "EDSA" and will begin trading on a...
Read more
LUND, SE / ACCESSWIRE / October 10, 2023 / BioInvent International (STO:BINV) The Phase 1 Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma.LUND, SWEDEN / ACCESSWIRE / October 10, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and...
Read more
ARUNDEL, AUSTRALIA / ACCESSWIRE / October 9, 2023 / China Dasheng Biotechnology Co. (OTC PINK:CDBT) advisors that the company has terminated the China Dasheng Biotechnology Co. Consulting Agreement with Kenneth Maciora, Empire Relations Group, Inc. and Empire Relations Holdings LLC.On July 10, 2023, CDBT entered the China Dasheng Biotechnology Co. Consulting Agreement which had a 3-month period expiring on October 10, 2023, with an upfront fee...
Read more
A joint study applying Genzeva's new breakthrough genomic research process reveals remarkable discovery by uncovering hidden "dark" data.ROCKVILLE, MD / ACCESSWIRE / October 6, 2023 / Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, has partnered with tech innovator RYLTI to develop an innovative groundbreaking application of AI Knowledge Engineering...
Read more
- 18 VenoValve patients enrolled over the final two months of the study- Surge in VenoValve demand exceeded the enrollment limit- Topline safety and efficacy readout and PMA eligibility now expected to occur in Q4 2023, Q2 2024, and Q3 2024, respectivelyIRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease,...
Read more
- enVVe development cycle to be reduced by 6 months- Application for enVVe pivotal trial now expected to be ready by end of 2024IRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced a plan to expedite the development of enVVe®, its transcatheter based replacement venous valve. The new plan...
Read more
Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trialUp to an additional $41 million of capital may become available from milestone-driven warrants upon expected FDA pre-market approval of the VenoValveIRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the...
Read more
Rigorous Audit Validates Auxilius as a Trusted Clinical Trial Financial Management Platform, a Key Element of Compliance and Assurance of Controls for the Highly Regulated Life Sciences IndustryMANHATTAN, NY / ACCESSWIRE / October 5, 2023 / Auxilius, the most widely used platform for clinical trial financial management, announced that it has successfully completed the Service Organization Control (SOC) 1 Type 2 audit. Conducted by Geels Norton...
Read more
Organic revenue growth of 12.6% in the first nine months of the financial year 2023Adjusted EBITDA up organically by 20.6%Order intake at record high: new orders for syringes and pens for GLP-1 drugsGuidance for full-year 2023 confirmedDUESSELDORF, GERMANY / ACCESSWIRE / October 5, 2023 / Gerresheimer, innovative provider of systems and solutions and global partner for the pharma, biotech, and cosmetics industries, made progress toward another...
Read more
Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) nonprescription pathways, announces completion of a pivotal label comprehension study (LCS). Using FDA guidance provided to the company in 2022, the LCS is expected to...
Read more
SAN DIEGO, CA / ACCESSWIRE / October 4, 2023 / XiltriX North America, LLC, a leading provider of real-time remote monitoring systems for the Life Science industry, is proud to announce the successful completion of its clean Service Organization Control (SOC) 2 Type 1 attestation report. This independent assessment of its internal security control demonstrates XiltriX's dedication and commitment to maintaining the highest standards of security...
Read more
GREENSBORO, NC and ANGUILLA, BRITISH WEST INDIES / ACCESSWIRE / October 3, 2023 / AT Research Partners is pleased to announce the issuance of US Patent #11,771,125 for a natural serotonin stimulant for appetite appeasement and weight loss, called Lactova™. Overweightness is not an invincible predator. Its causes surround us in plain sight. The epidemic is endemic to ordinary, perfectly normal biology. In cultures of abundant food and universal...
Read more
Proceeds to be used to complete corporate rebranding, accelerate acquisition pipeline, and attract additional investmentTAMPA, FL / ACCESSWIRE / October 3, 2023 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it completed the divestiture of a medical device used in spinal surgeries to a leading international medical device...
Read more
